Data gathered: January 29
AI Stock Analysis - X4 Pharmaceuticals (XFOR)
Analysis generated January 27, 2025. Powered by Chat GPT.
X4 Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for the treatment of rare diseases. The company's primary area of expertise lies in immuno-oncology, chronic diseases, and genetic disorders. The firm has been active in clinical research, aiming to bring innovative treatments to market. Despite the potential within the pharmaceutical industry, X4 Pharmaceuticals faces the challenges of high research and development costs, long drug development timelines, and the competitive nature of the sector.
Stock Alerts - X4 Pharmaceuticals (XFOR)
 |
X4 Pharmaceuticals | January 28 Insider Alert: Ragan Paula is selling shares |
|
X4 Pharmaceuticals | January 27 Price is down by -5.8% in the last 24h. |
|
X4 Pharmaceuticals | January 24 Price is down by -5.4% in the last 24h. |
|
X4 Pharmaceuticals | January 23 Price is up by 6.4% in the last 24h. |
Alternative Data for X4 Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 98 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | 20 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,076 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,005 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 137 | Sign up | Sign up | Sign up |
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $0.46 |
| Target Price | Sign up |
| Volume | 418,190 |
| Market Cap | $84M |
| Year Range | $0.28 - $1.11 |
| Dividend Yield | 0% |
| PE Ratio | 2.85 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application for Mavorixafor for the Treatment of WHIM SyndromeJanuary 26 - Finnhub |
|
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application for Mavorixafor, licenced to Norgine for commercialisation in EuropeJanuary 26 - Finnhub |
|
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM SyndromeJanuary 24 - GlobeNewswire |
|
 |
Head to Head Review: X4 Pharmaceuticals (NASDAQ:XFOR) and Curis (NASDAQ:CRIS)January 14 - ETF Daily News |
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New ZealandJanuary 13 - GlobeNewswire |
|
|
Brookline Capital Management Predicts XFOR FY2024 EarningsJanuary 10 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 560,000 | 230,000 | 330,000 | -37M | -34M | -0.180 |
| Q2 '24 | 560,000 | 270,000 | 300,000 | 91M | 93M | -0.070 |
| Q1 '24 | 0 | 0 | -19M | -52M | -50M | -0.260 |
| Q4 '23 | 24M | 9.9M | -12M | -19M | -17M | -0.100 |
| Q3 '23 | 0 | 0 | -9.7M | -2.3M | -26M | -0.010 |
Insider Transactions View All
| Arbet-Engels Christophe filed to sell 14,207 shares at $0.5. January 27 '25 |
| DiBiase Mary filed to sell 490,980 shares at $0.5. January 27 '25 |
| Baldry Mark filed to sell 94,123 shares at $0.5. January 27 '25 |
| Ragan Paula filed to sell 1,087,386 shares at $0.5. January 27 '25 |
Similar companies
Read more about X4 Pharmaceuticals (XFOR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of X4 Pharmaceuticals?
The Market Cap of X4 Pharmaceuticals is $84M.
What is X4 Pharmaceuticals' PE Ratio?
As of today, X4 Pharmaceuticals' PE (Price to Earnings) ratio is 2.85.
What is the current stock price of X4 Pharmaceuticals?
Currently, the price of one share of X4 Pharmaceuticals stock is $0.46.
How can I analyze the XFOR stock price chart for investment decisions?
The XFOR stock price chart above provides a comprehensive visual representation of X4 Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling X4 Pharmaceuticals shares. Our platform offers an up-to-date XFOR stock price chart, along with technical data analysis and alternative data insights.
Does XFOR offer dividends to its shareholders?
As of our latest update, X4 Pharmaceuticals (XFOR) does not offer dividends to its shareholders. Investors interested in X4 Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of X4 Pharmaceuticals?
Some of the similar stocks of X4 Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.